Eyre TA, Hildyard C, Hamblin A, et al. - Among patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), researchers evaluated vistusertib (oral dual mTORC1/2 inhibitor) in an intermittent dosing schedule of 125 mg BD for 2 days per week. A total of 30 patients were administered vistusertib and 6 were given vistusertib-rituximab for up to six cycles (28-day cycles). Monotherapy provided 2 partial responses. The reported response durations were 57 and 62 days, respectively. A median progression-free survival of 1.69 months and a median overall survival of 6.58 months, respectively, was reported in the monotherapy arm. Good tolerability of vistusertib ± rituximab was evident; across 36 patients 86% of adverse events were grade (G) 1-2. Experts concluded that no clear benefit was provided by dual mTORC1/2 inhibitors over mTORC1 inhibitors in relapsed or refractory DLBCL.